In addition, pharmacological dampening of PI3K signaling in lupus-prone mice provides evidence for the therapeutic potential of targeting PI3K/Akt/mTORC1 pathway in SLE (52). The gene discussed is AKT1; the disease is systemic lupus erythematosus.